Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

AbbVie, Lilly Face New Delays in FDA Approval for Expanded Use of Janus Kinase Inhibitors

  |  

(Reuters)—AbbVie Inc. and ELi Lilly & Co. are facing fresh delays in the approval of their respective rheumatoid arthritis (RA) drugs for treating the chronic skin disease eczema as the U.S. health regulator assesses the new class of treatment over safety concerns. The treatment, called Janus kinase inhibitors (jakinibs), blocks inflammation-causing enzymes known as Janus…

CDC Advisers Consider Boosters for Immune-Compromised Americans

Julie Steenhuysen  |  

CHICAGO (Reuters)—Advisers to the U.S. Centers for Disease Control & Prevention will consider evidence suggesting that a booster dose of COVID-19 vaccines could increase protection among people with compromised immune systems. Data presented ahead of the July 22 meeting noted that people with compromised immune systems have a reduced antibody response following the recommended primary…

Learn to Share Your Voice at Advocacy 101

  |  

Applications are now open for the ACR’s Advocacy 101 program, held in conjunction with Advocates for Arthritis. Amanda Schnell, MD, describes how ACR/ARP members can learn to be successful advocates for rheumatology.

2022 Physician Fee Schedule Proposed Rule Released

  |  

In the proposed rule released July 13, the ACR is encouraged by the continued implementation of evaluation and management reimbursement adjustments to better reflect the work and expertise needed to treat complex patient populations, the extension of many telehealth flexibilities and the inclusion of the ACR’s proposed MACRA MIPS Value Pathway for rheumatology.